<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Human pegivirus-1 infection</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Human pegivirus-1 infection</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Human pegivirus-1 infection</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sanjiv Chopra, MD, MACP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Adrian M Di Bisceglie, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 01, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Human pegivirus (HPgV-1), previously designated hepatitis G virus (HGV) and GB virus type C (GBV-C), is a single-stranded positive RNA virus belonging to the <em>Flaviviridae</em> family [<a href="#rid1">1</a>]. </p><p>HPgV-1 was initially cloned from a surgeon (whose initials were GB, hence the term GB virus or GBV). Plasma from this patient transmitted hepatitis to tamarins. Three different GBV agents were isolated and designed GB virus types A, B, and C; the first two were probably tamarin agents [<a href="#rid2">2</a>]. The agent designated GBV-C is virtually identical to HGV. Because GBV-C/HGV infects human beings, it was renamed as human pegivirus type 1 (HPgV-1).</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>HPgV-1 has a global distribution. It is estimated that one-sixth of the global population is seropositive for HPgV-1, and approximately 750 million people have had viremia [<a href="#rid1">1</a>]. In one meta-analysis of 35,468 volunteer blood donors, the global prevalence of HPgV-1 was 3.1 percent [<a href="#rid3">3</a>]. The pooled prevalence rates varied by continent, with rates of 1.7 percent in North America, 2.3 percent in Europe, 2.4 percent in Asia, and 9.1 percent in South America. Reported rates of viremia are higher in individuals with hepatitis C virus (HCV; 11 to 24 percent) and HIV (42 percent) [<a href="#rid4">4,5</a>].</p><p class="headingAnchor" id="H1813283501"><span class="h1">TRANSMISSION</span><span class="headingEndMark"> — </span>Infection is transmitted by transfusion of contaminated blood, through sexual contact, and via vertical transmission, similar to HCV and hepatitis B virus (HBV) [<a href="#rid6">6,7</a>]. Due to shared risk factors, co-infection with HIV-1 and/or HCV are high. (See <a class="local">'Epidemiology'</a> above.)</p><p class="headingAnchor" id="H1177384414"><span class="h1">VIROLOGY</span></p><p class="headingAnchor" id="H3902917678"><span class="h2">Composition and structure</span><span class="headingEndMark"> — </span>HPgV-1 is a spherical enveloped virus approximately 50 nm in diameter [<a href="#rid8">8</a>]. HPgV-1 genome encodes a long open reading frame (ORF) that is translated into a single pre-polyprotein consisting of approximately 3000 amino acid residues. The coding region is flanked by long 5’ and 3’ untranslated regions (UTRs). The pre-polyprotein is cleaved into two structural proteins (envelope proteins E1 and E2) and six non-structural proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B) by cellular signal peptidases and two viral proteases [<a href="#rid9">9,10</a>].</p><p class="headingAnchor" id="H495845269"><span class="h2">Genotypes</span><span class="headingEndMark"> — </span>Based on genetic diversity, there are seven identified genotypes with varying global distribution. HPgV-1 genotypes 1 and 2 are prevalent in Africa [<a href="#rid11">11</a>]; genotype 2 is more prevalent in the United States and Europe [<a href="#rid12">12,13</a>]; genotype 3 is prevalent in Asia and South America [<a href="#rid14">14,15</a>]; genotype 4 and 5 in Southeast Asia [<a href="#rid16">16</a>]; genotype 6 has been reported in Indonesia [<a href="#rid17">17</a>]; and genotype 7 in China and Qatar [<a href="#rid18">18</a>]. </p><p class="headingAnchor" id="H4221365837"><span class="h1">NATURAL HISTORY AND CLINICAL IMPLICATIONS</span><span class="headingEndMark"> — </span>HPgV-1 infection typically lasts for &gt;6 months and is cleared spontaneously in more than 50 percent of infections within two years [<a href="#rid19">19</a>]. The exact role, if any, of HPgV-1 in producing disease in humans remains unclear [<a href="#rid20">20</a>]. HPgV viremia has been associated with an increased risk of lymphoma [<a href="#rid21">21</a>]. It may also have an impact on the disease course in patients with HIV or hepatitis C virus (HCV) coinfection. (See <a class="local">'Impact on co-infections'</a> below.)</p><p class="headingAnchor" id="H1210376696"><span class="h2">Role in causing liver disease</span><span class="headingEndMark"> — </span>The preponderance of evidence suggests that HPgV-1 does not cause hepatitis in humans [<a href="#rid20">20,22</a>]. In one report, approximately 75 percent of individuals positive for HPgV-1 RNA had normal serum aminotransferase levels [<a href="#rid6">6</a>]. While some studies suggested that HPgV-1 was associated with acute fulminant hepatitis [<a href="#rid23">23,24</a>], other reports have confirmed that the presence of HPgV-1 RNA in patients with fulminant hepatitis of unknown etiology was related to the administration of blood products after the onset of disease [<a href="#rid25">25,26</a>].</p><p>HPgV-1 RNA has been detected in patients with acute non-A to non-E viral hepatitis, in patients with chronic hepatitis of presumed viral etiology, in patients with cryptogenic cirrhosis, and in some patients with primary hepatocellular carcinoma. However, it is often difficult to tease out the direct role of HPgV-1 in these settings since coinfection with HCV is common [<a href="#rid27">27</a>]. There are no prospective studies that have documented histologically the progression from acute HPgV-1 infection through various stages of chronic liver disease, such as chronic hepatitis, cirrhosis, and primary hepatocellular carcinoma. In patients with chronic non-A to non-E hepatitis or cryptogenic cirrhosis, there is no evidence that, if present, HPgV-1 is the cause of the disease, rather than being an innocent bystander [<a href="#rid28">28,29</a>].</p><p class="headingAnchor" id="H2249375982"><span class="h2">Impact on co-infections</span></p><p class="headingAnchor" id="H4"><span class="h3">Patients with HIV co-infection</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Improved HIV outcomes — </strong>Accumulating evidence suggests a protective effect of HPgV-1 on patients co-infected with HIV [<a href="#rid30">30-34</a>]. In patients with HIV, HPgV-1 viremia has been associated with slower disease progression and lower mortality [<a href="#rid32">32,35</a>]. This was illustrated in a prospective cohort study of 271 men who were assessed for HPgV-1 viremia 12 to 18 months after HIV seroconversion and a subgroup of 138 patients who were evaluated again five to six years after HIV seroconversion [<a href="#rid35">35</a>]. At baseline, 231 men (85 percent) had evidence of current or previous infection. HPgV-1 status was not significantly associated with survival at 12 to 18 months following HIV seroconversion. However, patients with persistent HPgV-1 viremia five to six years after HIV seroconversion had significantly longer survival as compared with those without HPgV-1 RNA. The poorest outcomes occurred among the 9 percent of patients who lost HPgV-1 RNA between the two time points (relative hazard of death of 5.87 compared to those with persistent HPgV-1 RNA).</p><p></p><p class="bulletIndent1">The protective effect of HPgV-1 may be related to maintenance of an intact T-helper 1 cytokine profile, the induction of HIV-inhibitory cytokines, and interference with HIV replication [<a href="#rid36">36,37</a>]. While the observations in these reports support further investigation into the mechanisms of interaction between HPgV-1 and HIV, the therapeutic implications remain unclear. </p><p></p><p class="bulletIndent1">There is little information on the natural history of HIV and HPgV-1 co-infection in patients who are receiving antiretroviral therapy for HIV; but the available data suggest that the protective effect of HPgV-1 co-infection may be less apparent [<a href="#rid38">38-40</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>No impact on vertical HIV transmission</strong> — HPgV-1 co-infection does not appear to mitigate or promote vertical transmission of HIV. In a retrospective cohort study of 186 pregnant persons with HIV, there were no differences in the rates of perinatal HIV transmission among the HPgV-1 RNA positive women and those without evidence of current or past HPgV-1 infection (28 versus 26 percent) [<a href="#rid41">41</a>].</p><p></p><p class="headingAnchor" id="H2530443271"><span class="h3">Patients with HCV co-infection</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HCV and HPgV-1 co-infection</strong> – Coinfection with HPgV-1 does not appear to impact the clinical course or outcomes of HCV infection, HCV-related chronic liver disease, hepatic fibrosis, or transaminase levels. In one study of 189 patients with chronic HCV infection, 21 (11 percent) were positive for HPgV-1 RNA, and there was no significant difference in the course of the HCV infection and the response to interferon-alfa in patients with and without co-infection with HPgV-1 [<a href="#rid42">42</a>]. Interferon-alfa led to a decrease in HPgV-1 RNA titers that was not sustained after the cessation of therapy. Similar findings were noted in another study in which liver biopsies were performed [<a href="#rid43">43</a>]. Detailed histopathologic examination revealed no difference between the patients infected with HCV alone and the 15 percent who were co-infected with HPgV-1 [<a href="#rid42">42</a>]. Data on the effect of HPgV-1 infection on treatment of HCV with interferon-free therapies are lacking. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HCV, HIV, and HPgV-1 co-infection</strong> – In patients with HCV/HIV coinfection, HPgV-1 viremia has been associated with a significant reduction in HCV-related liver morbidity. In a study of 158 HCV/HIV co-infected patients, in which 57 (26 percent) patients had HPgV-1 RNA and 94 (59 percent) had evidence of past exposure based upon results of antibody testing, active HPgV-1 was independently associated with a significant reduction in the risk of compensated and decompensated cirrhosis (HR 0.27, 95% CI 0.08-0.88) [<a href="#rid34">34</a>]. </p><p></p><p class="headingAnchor" id="H3642370893"><span class="h1">DIAGNOSTIC TESTS</span><span class="headingEndMark"> — </span>Active infection is diagnosed by detecting its RNA in the serum by polymerase chain reaction. However, the sensitivity and specificity of this test are not known [<a href="#rid2">2</a>] and may significantly underestimate the true incidence of infection [<a href="#rid44">44</a>]. Appearance of antibodies to the major viral envelope glycoprotein (E2) are associated with the clearance of viremia [<a href="#rid45">45</a>]. There are no commercial assays available for either HPgV-1 antibodies or RNA. </p><p class="headingAnchor" id="H5"><span class="h1">NO ROLE FOR ROUTINE BLOOD DONOR SCREENING</span><span class="headingEndMark"> — </span>Routine screening for HPgV-1 is <strong>not</strong> performed in blood donors. Whether donor blood should be screened for HPgV-1 and other viruses that have been discovered in human blood but are not known to cause disease is a contentious issue. </p><p>Arguments against donor screening include:</p><p class="bulletIndent1"><span class="glyph">●</span>The potential for high donor loss.</p><p class="bulletIndent1"><span class="glyph">●</span>The apparently very low incidence of posttransfusion hepatitis [<a href="#rid46">46</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>The apparently mild disease when acute hepatitis does occur.</p><p class="bulletIndent1"><span class="glyph">●</span>The lack of proof that chronic liver disease occurs with HPgV-1 infection.</p><p class="bulletIndent1"><span class="glyph">●</span>The apparently very low disease burden due to HPgV-1.</p><p class="bulletIndent1"><span class="glyph">●</span>The difficulty in counseling otherwise healthy blood donors.</p><p></p><p class="headingAnchor" id="H7"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence –</strong> Human pegivirus (HPgV-1), previously designated hepatitis G virus (HGV) and GB virus type C (GBV-C), has a global distribution. It is estimated that one-sixth of the world population is seropositive for HPgV-1, and approximately 750 million individuals have had viremia. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Virology</strong> <strong>–</strong> HPgV-1 is a single-stranded positive RNA virus belonging to the <em>Flaviviridae</em> family. It is a spherical enveloped virus approximately 50 nm in diameter. Based on genetic diversity, there are seven identified genotypes with varying global distribution. (See <a class="local">'Genotypes'</a> above and <a class="local">'Composition and structure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transmission</strong> <strong>–</strong> HPgV-1 is transmitted by transfusion of contaminated blood, through sexual contact, and via vertical transmission. Active infection is diagnosed by detecting its RNA in the serum by polymerase chain reaction. However, the sensitivity and specificity of this test are not known. (See <a class="local">'Transmission'</a> above and <a class="local">'Diagnostic tests'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Natural history</strong> <strong>–</strong> HPgV-1 infection typically lasts for &gt;6 months and is cleared spontaneously in more than 50 percent of infections within two years. Appearance of antibodies to the major viral envelope glycoprotein (E2) is associated with the clearance of viremia. (See <a class="local">'Natural history and clinical implications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical significance </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The preponderance of evidence suggests that HPgV-1 does not cause hepatitis in humans. However, viremia has been associated with an increased risk of lymphoma. (See <a class="local">'Role in causing liver disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with HIV, HPgV-1 viremia has been associated with slower disease progression and lower mortality. (See <a class="local">'Patients with HIV co-infection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with HIV/hepatitis C virus (HCV) coinfection, HPgV-1 viremia has been associated with a significant reduction in HCV-related liver morbidity. (See <a class="local">'Patients with HCV co-infection'</a> above.)</p><p></p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Yu Y, Wan Z, Wang JH, et al. Review of human pegivirus: Prevalence, transmission, pathogenesis, and clinical implication. Virulence 2022; 13:324.</a></li><li><a class="nounderline abstract_t">Di Bisceglie AM. Hepatitis G virus infection: a work in progress. Ann Intern Med 1996; 125:772.</a></li><li><a class="nounderline abstract_t">Yang N, Dai R, Zhang X. Global prevalence of human pegivirus-1 in healthy volunteer blood donors: a systematic review and meta-analysis. Vox Sang 2020; 115:107.</a></li><li><a class="nounderline abstract_t">Rey D, Vidinic-Moularde J, Meyer P, et al. High prevalence of GB virus C/hepatitis G virus RNA and antibodies in patients infected with human immunodeficiency virus type 1. Eur J Clin Microbiol Infect Dis 2000; 19:721.</a></li><li><a class="nounderline abstract_t">Berzsenyi MD, Bowden DS, Roberts SK. GB virus C: insights into co-infection. J Clin Virol 2005; 33:257.</a></li><li><a class="nounderline abstract_t">Alter HJ. The cloning and clinical implications of HGV and HGBV-C. N Engl J Med 1996; 334:1536.</a></li><li><a class="nounderline abstract_t">Frey SE, Homan SM, Sokol-Anderson M, et al. Evidence for probable sexual transmission of the hepatitis g virus. Clin Infect Dis 2002; 34:1033.</a></li><li><a class="nounderline abstract_t">Marano G, Franchini M, Farina B, et al. The human pegivirus: A new name for an "ancient" virus. Can transfusion medicine come up with something new? Acta Virol 2017; 61:401.</a></li><li><a class="nounderline abstract_t">Belyaev AS, Chong S, Novikov A, et al. Hepatitis G virus encodes protease activities which can effect processing of the virus putative nonstructural proteins. J Virol 1998; 72:868.</a></li><li><a class="nounderline abstract_t">George SL, Varmaz D, Tavis JE, Chowdhury A. The GB virus C (GBV-C) NS3 serine protease inhibits HIV-1 replication in a CD4+ T lymphocyte cell line without decreasing HIV receptor expression. PLoS One 2012; 7:e30653.</a></li><li><a class="nounderline abstract_t">de Pina-Araujo IIM, Horta MA, do Amaral Mello FC, Soares CC. Human pegivirus 1 in Cabo Verde: prevalence and genotypic distribution among HIV-infected individuals. Arch Virol 2021; 166:1345.</a></li><li><a class="nounderline abstract_t">Neibecker M, Schwarze-Zander C, Rockstroh JK, et al. Evidence for extensive genotypic diversity and recombination of GB virus C (GBV-C) in Germany. J Med Virol 2011; 83:685.</a></li><li><a class="nounderline abstract_t">Jõgeda EL, Huik K, Pauskar M, et al. Prevalence and genotypes of GBV-C and its associations with HIV infection among persons who inject drugs in Eastern Europe. J Med Virol 2017; 89:632.</a></li><li><a class="nounderline abstract_t">Loureiro CL, Alonso R, Pacheco BA, et al. High prevalence of GB virus C/hepatitis G virus genotype 3 among autochthonous Venezuelan populations. J Med Virol 2002; 68:357.</a></li><li><a class="nounderline abstract_t">Li Z, Li Y, Liang Y, et al. Prevalence and risk factors of human pegivirus type 1 infection in hematopoietic stem cell transplantation patients. Int J Infect Dis 2019; 85:111.</a></li><li><a class="nounderline abstract_t">Naito H, Abe K. Genotyping system of GBV-C/HGV type 1 to type 4 by the polymerase chain reaction using type-specific primers and geographical distribution of viral genotypes. J Virol Methods 2001; 91:3.</a></li><li><a class="nounderline abstract_t">Anggorowati N, Yano Y, Subronto YW, et al. GB virus C infection in Indonesian HIV-positive patients. Microbiol Immunol 2013; 57:298.</a></li><li><a class="nounderline abstract_t">Feng Y, Zhao W, Feng Y, et al. A novel genotype of GB virus C: its identification and predominance among injecting drug users in Yunnan, China. PLoS One 2011; 6:e21151.</a></li><li><a class="nounderline abstract_t">Tanaka E, Kiyosawa K, Shimoda K, et al. Evolution of hepatitis G virus infection and antibody response to envelope protein in patients with transfusion-associated non-A, non-B hepatitis. J Viral Hepat 1998; 5:153.</a></li><li><a class="nounderline abstract_t">Theodore D, Lemon SM. GB virus C, hepatitis G virus, or human orphan flavivirus? Hepatology 1997; 25:1285.</a></li><li><a class="nounderline abstract_t">Fama A, Larson MC, Link BK, et al. Human Pegivirus Infection and Lymphoma Risk: A Systematic Review and Meta-analysis. Clin Infect Dis 2020; 71:1221.</a></li><li><a class="nounderline abstract_t">Feucht HH, Zöllner B, Polywka S, et al. Distribution of hepatitis G viremia and antibody response to recombinant proteins with special regard to risk factors in 709 patients. Hepatology 1997; 26:491.</a></li><li><a class="nounderline abstract_t">Yoshiba M, Okamoto H, Mishiro S. Detection of the GBV-C hepatitis virus genome in serum from patients with fulminant hepatitis of unknown aetiology. Lancet 1995; 346:1131.</a></li><li><a class="nounderline abstract_t">da Silva AS, de Campos GM, Villanova MG, et al. Human Pegivirus-1 Detection and Genotyping in Brazilian Patients with Fulminant Hepatitis. Pathogens 2023; 12.</a></li><li><a class="nounderline abstract_t">Kanda T, Yokosuka O, Ehata T, et al. Detection of GBV-C RNA in patients with non-A-E fulminant hepatitis by reverse-transcription polymerase chain reaction. Hepatology 1997; 25:1261.</a></li><li><a class="nounderline abstract_t">Muñoz SJ, Alter HJ, Nakatsuji Y, et al. The significance of hepatitis G virus in serum of patients with sporadic fulminant and subfulminant hepatitis of unknown etiology. Blood 1999; 94:1460.</a></li><li><a class="nounderline abstract_t">Ng KT, Takebe Y, Chook JB, et al. Co-infections and transmission networks of HCV, HIV-1 and HPgV among people who inject drugs. Sci Rep 2015; 5:15198.</a></li><li><a class="nounderline abstract_t">Fried MW, Khudyakov YE, Smallwood GA, et al. Hepatitis G virus co-infection in liver transplantation recipients with chronic hepatitis C and nonviral chronic liver disease. Hepatology 1997; 25:1271.</a></li><li><a class="nounderline abstract_t">Vargas HE, Laskus T, Radkowski M, et al. Hepatitis G virus coinfection in hepatitis C virus-infected liver transplant recipients. Transplantation 1997; 64:786.</a></li><li><a class="nounderline abstract_t">Yeo AE, Matsumoto A, Hisada M, et al. Effect of hepatitis G virus infection on progression of HIV infection in patients with hemophilia. Multicenter Hemophilia Cohort Study. Ann Intern Med 2000; 132:959.</a></li><li><a class="nounderline abstract_t">Lefrère JJ, Roudot-Thoraval F, Morand-Joubert L, et al. Carriage of GB virus C/hepatitis G virus RNA is associated with a slower immunologic, virologic, and clinical progression of human immunodeficiency virus disease in coinfected persons. J Infect Dis 1999; 179:783.</a></li><li><a class="nounderline abstract_t">Xiang J, Wünschmann S, Diekema DJ, et al. Effect of coinfection with GB virus C on survival among patients with HIV infection. N Engl J Med 2001; 345:707.</a></li><li><a class="nounderline abstract_t">Tillmann HL, Heiken H, Knapik-Botor A, et al. Infection with GB virus C and reduced mortality among HIV-infected patients. N Engl J Med 2001; 345:715.</a></li><li><a class="nounderline abstract_t">Berzsenyi MD, Bowden DS, Kelly HA, et al. Reduction in hepatitis C-related liver disease associated with GB virus C in human immunodeficiency virus coinfection. Gastroenterology 2007; 133:1821.</a></li><li><a class="nounderline abstract_t">Williams CF, Klinzman D, Yamashita TE, et al. Persistent GB virus C infection and survival in HIV-infected men. N Engl J Med 2004; 350:981.</a></li><li><a class="nounderline abstract_t">Nunnari G, Nigro L, Palermo F, et al. Slower progression of HIV-1 infection in persons with GB virus C co-infection correlates with an intact T-helper 1 cytokine profile. Ann Intern Med 2003; 139:26.</a></li><li><a class="nounderline abstract_t">Xiang J, George SL, Wünschmann S, et al. Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1alpha, MIP-1beta, and SDF-1. Lancet 2004; 363:2040.</a></li><li><a class="nounderline abstract_t">Soriano-Sarabia N, Abad MA, Vallejo A, et al. Influence of hepatitis C and hepatitis G virus co-infection on viral and cellular dynamics in patients infected with human immunodeficiency virus following interruption of highly active anti-retroviral therapy. Clin Microbiol Infect 2006; 12:290.</a></li><li><a class="nounderline abstract_t">Piroth L, Carrat F, Larrat S, et al. Prevalence and impact of GBV-C, SEN-V and HBV occult infections in HIV-HCV co-infected patients on HCV therapy. J Hepatol 2008; 49:892.</a></li><li><a class="nounderline abstract_t">Campos AF, Tengan FM, Silva SA, Levi JE. Influence of hepatitis G virus (GB virus C) on the prognosis of HIV-infected women. Int J STD AIDS 2011; 22:209.</a></li><li><a class="nounderline abstract_t">Weintrob AC, Hamilton JD, Hahn C, et al. Active or prior GB virus C infection does not protect against vertical transmission of HIV in coinfected women from Tanzania. Clin Infect Dis 2004; 38:e46.</a></li><li><a class="nounderline abstract_t">Tanaka E, Alter HJ, Nakatsuji Y, et al. Effect of hepatitis G virus infection on chronic hepatitis C. Ann Intern Med 1996; 125:740.</a></li><li><a class="nounderline abstract_t">Bralet MP, Roudot-Thoraval F, Pawlotsky JM, et al. Histopathologic impact of GB virus C infection on chronic hepatitis C. Gastroenterology 1997; 112:188.</a></li><li><a class="nounderline abstract_t">Thomas DL, Vlahov D, Alter HJ, et al. Association of antibody to GB virus C (hepatitis G virus) with viral clearance and protection from reinfection. J Infect Dis 1998; 177:539.</a></li><li><a class="nounderline abstract_t">Tacke M, Schmolke S, Schlueter V, et al. Humoral immune response to the E2 protein of hepatitis G virus is associated with long-term recovery from infection and reveals a high frequency of hepatitis G virus exposure among healthy blood donors. Hepatology 1997; 26:1626.</a></li><li><a class="nounderline abstract_t">Jarvis LM, Davidson F, Hanley JP, et al. Infection with hepatitis G virus among recipients of plasma products. Lancet 1996; 348:1352.</a></li></ol></div><div id="topicVersionRevision">Topic 3660 Version 17.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35132924" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Review of human pegivirus: Prevalence, transmission, pathogenesis, and clinical implication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8929013" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Hepatitis G virus infection: a work in progress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31845353" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Global prevalence of human pegivirus-1 in healthy volunteer blood donors: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11057510" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : High prevalence of GB virus C/hepatitis G virus RNA and antibodies in patients infected with human immunodeficiency virus type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15922655" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : GB virus C: insights into co-infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8618611" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The cloning and clinical implications of HGV and HGBV-C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11914990" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Evidence for probable sexual transmission of the hepatitis g virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29186957" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The human pegivirus: A new name for an "ancient" virus. Can transfusion medicine come up with something new?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9420302" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Hepatitis G virus encodes protease activities which can effect processing of the virus putative nonstructural proteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22292009" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The GB virus C (GBV-C) NS3 serine protease inhibits HIV-1 replication in a CD4+ T lymphocyte cell line without decreasing HIV receptor expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33689039" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Human pegivirus 1 in Cabo Verde: prevalence and genotypic distribution among HIV-infected individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21328384" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Evidence for extensive genotypic diversity and recombination of GB virus C (GBV-C) in Germany.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27603233" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Prevalence and genotypes of GBV-C and its associations with HIV infection among persons who inject drugs in Eastern Europe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12226822" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : High prevalence of GB virus C/hepatitis G virus genotype 3 among autochthonous Venezuelan populations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31170546" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Prevalence and risk factors of human pegivirus type 1 infection in hematopoietic stem cell transplantation patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11164480" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Genotyping system of GBV-C/HGV type 1 to type 4 by the polymerase chain reaction using type-specific primers and geographical distribution of viral genotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23590588" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : GB virus C infection in Indonesian HIV-positive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21998624" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A novel genotype of GB virus C: its identification and predominance among injecting drug users in Yunnan, China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9658367" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Evolution of hepatitis G virus infection and antibody response to envelope protein in patients with transfusion-associated non-A, non-B hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9141455" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : GB virus C, hepatitis G virus, or human orphan flavivirus?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31671178" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Human Pegivirus Infection and Lymphoma Risk: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9252164" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Distribution of hepatitis G viremia and antibody response to recombinant proteins with special regard to risk factors in 709 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7475605" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Detection of the GBV-C hepatitis virus genome in serum from patients with fulminant hepatitis of unknown aetiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37764930" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Human Pegivirus-1 Detection and Genotyping in Brazilian Patients with Fulminant Hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9141449" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Detection of GBV-C RNA in patients with non-A-E fulminant hepatitis by reverse-transcription polymerase chain reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10438734" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The significance of hepatitis G virus in serum of patients with sporadic fulminant and subfulminant hepatitis of unknown etiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26459957" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Co-infections and transmission networks of HCV, HIV-1 and HPgV among people who inject drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9141451" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Hepatitis G virus co-infection in liver transplantation recipients with chronic hepatitis C and nonviral chronic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9311724" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Hepatitis G virus coinfection in hepatitis C virus-infected liver transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10858179" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Effect of hepatitis G virus infection on progression of HIV infection in patients with hemophilia. Multicenter Hemophilia Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10068572" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Carriage of GB virus C/hepatitis G virus RNA is associated with a slower immunologic, virologic, and clinical progression of human immunodeficiency virus disease in coinfected persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11547739" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effect of coinfection with GB virus C on survival among patients with HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11547740" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Infection with GB virus C and reduced mortality among HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18054555" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Reduction in hepatitis C-related liver disease associated with GB virus C in human immunodeficiency virus coinfection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14999110" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Persistent GB virus C infection and survival in HIV-infected men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12834315" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Slower progression of HIV-1 infection in persons with GB virus C co-infection correlates with an intact T-helper 1 cytokine profile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15207954" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1alpha, MIP-1beta, and SDF-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16451419" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Influence of hepatitis C and hepatitis G virus co-infection on viral and cellular dynamics in patients infected with human immunodeficiency virus following interruption of highly active anti-retroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18752863" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Prevalence and impact of GBV-C, SEN-V and HBV occult infections in HIV-HCV co-infected patients on HCV therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21515753" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Influence of hepatitis G virus (GB virus C) on the prognosis of HIV-infected women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14999645" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Active or prior GB virus C infection does not protect against vertical transmission of HIV in coinfected women from Tanzania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8929008" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Effect of hepatitis G virus infection on chronic hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8978358" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Histopathologic impact of GB virus C infection on chronic hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9498429" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Association of antibody to GB virus C (hepatitis G virus) with viral clearance and protection from reinfection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9398008" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Humoral immune response to the E2 protein of hepatitis G virus is associated with long-term recovery from infection and reveals a high frequency of hepatitis G virus exposure among healthy blood donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8918279" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Infection with hepatitis G virus among recipients of plasma products.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
